BioPharmSignal logoBioPharmSignal

Biotech News

Revolution Medicines to Participate in November 2026 Investor Conferences

Revolution Medicines (RVMD)Revolution MedicinesCommercial

REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that Mark A.

Related news

SNDXSyndax Pharmaceuticals2026-10-30 11:00 EST

Syndax Announces Participation in November Investor Conferences

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

KURAKura Oncology2026-10-07 11:15 EST

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

KPTIKaryopharm Therapeutics2026-10-01 20:05 EST

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-10-12 11:00 EST

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

SNYSanofi2026-10-12 16:05 EST

Sanofi: Information concerning the total number of voting rights and shares – September 2026

View all latest news

Revolution Medicines

RAS(ON) Inhibitors Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins. Its portfolio covers multiple RAS mutations and combination strategies across pancreatic and lung cancers. Daraxonrasib Daraxonrasib is a multi-selective RAS(ON) inhibitor and the company's lead late-stage asset. It has...

Recent company news

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

RVMDRevolution Medicines2026-10-23 11:30 EST

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

Stock data

Close
177.65 USD
Market cap
32.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States